Comparison	Number of Studies	Direct Evidence	I2	Fixed effect model	OR	95%-CI
Ari vs Pali Direct estimate Indirect estimate Network estimate	2	0.43	0.00		0.90 1.48 1.19	[0.42; 1.92] [0.76; 2.87] [0.72; 1.96]
Ari vs Pcb Direct estimate Indirect estimate Network estimate	3	0.64	0.00		0.85 0.52 0.71	[0.46; 1.56] [0.23; 1.15] [0.44; 1.15]
Pali vs Pcb Direct estimate Indirect estimate Network estimate	5	0.73	0.03	-	0.53 0.82 0.60	[0.39; 0.72] [0.50; 1.34] [0.46; 0.77]
Pali vs Risp Direct estimate Indirect estimate Network estimate	3	0.83	0.52		1.40 1.00 1.32	[1.07; 1.83] [0.56; 1.80] [1.03; 1.68]
Risp vs Pcb Direct estimate Indirect estimate Network estimate	2	0.37	0.00	0.5 1 2	0.56 0.40 0.45	[0.33; 0.93] [0.27; 0.59] [0.33; 0.62]

Supplementary Figure 2. Netsplit for STEAEs. Arip, aripiprazole; Pali, paliperidone; Pcb, placebo; Risp, risperidone; OR, odds ratio; Cl, confidence interval; STEAEs, serious treatment emergent adverse events.